Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. cut its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 8.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,122 shares of the biopharmaceutical company’s stock after selling 891 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Dynavax Technologies were worth $116,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its stake in Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,034 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new position in Dynavax Technologies in the 4th quarter worth $71,000. Nisa Investment Advisors LLC lifted its position in Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 1,076 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new stake in Dynavax Technologies during the 3rd quarter valued at about $89,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, The Goldman Sachs Group cut shares of Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their target price for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th.

Dynavax Technologies Price Performance

NASDAQ:DVAX opened at $13.84 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The company has a 50 day moving average price of $13.24 and a 200-day moving average price of $12.43. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $14.63. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of 76.89 and a beta of 1.23.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million. Equities research analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.